Dusan Stefoski to Humans
This is a "connection" page, showing publications Dusan Stefoski has written about Humans.
Connection Strength
0.178
-
Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019 May; 6(5):923-931.
Score: 0.036
-
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 Oct; 13(5):261-268.
Score: 0.012
-
Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders. J Neurol Sci. 2023 08 15; 451:120693.
Score: 0.012
-
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 05; 29(6):719-730.
Score: 0.012
-
The rare case of a 20-year-old male with rapidly progressive primary angiitis of the CNS with a good outcome. Neurol Neuroimmunol Neuroinflamm. 2020 09; 7(5).
Score: 0.010
-
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. J Neurol. 2020 Oct; 267(10):2851-2864.
Score: 0.010
-
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016 Jul 26; 16:117.
Score: 0.007
-
Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. JAMA Neurol. 2014 Aug; 71(8):1025-9.
Score: 0.006
-
Is cervical decompression beneficial in patients with coexistent cervical stenosis and multiple sclerosis? J Clin Neurosci. 2014 Dec; 21(12):2189-93.
Score: 0.006
-
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014 May; 13(5):472-81.
Score: 0.006
-
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler. 2014 Apr; 20(4):464-70.
Score: 0.006
-
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Jun 22; 381(9884):2167-75.
Score: 0.006
-
Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica. J Immunol. 2012 Nov 01; 189(9):4602-11.
Score: 0.006
-
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology. 2011 Sep 06; 77(10):1020; author reply 1020.
Score: 0.005
-
IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination. J Neuroimmunol. 2011 Apr; 233(1-2):147-59.
Score: 0.005
-
Freedom from disease activity in multiple sclerosis. Neurology. 2010 Apr 27; 74 Suppl 3:S3-7.
Score: 0.005
-
Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):16-21.
Score: 0.005
-
A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol. 2009 Jun 25; 211(1-2):124-30.
Score: 0.004
-
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 Mar; 8(3):254-60.
Score: 0.004
-
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009 Mar; 8(3):244-53.
Score: 0.004
-
Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood. 2007 Mar 15; 109(6):2643-548.
Score: 0.004
-
Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol. 2005 Jun; 62(6):860-4.
Score: 0.003
-
Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. 2003 Oct 01; 102(7):2373-8.
Score: 0.003